Cardiac mitochondrion

Cardiac mitochondria are highly specialized populations of mitochondria within heart muscle cells (cardiomyocytes), accounting for over 30% of the cell volume and producing about 90–95% of the heart's ATP via oxidative phosphorylation. These organelles tightly regulate cardiac energy supply, fatty acid oxidation, redox (ROS) balance, and cell death pathways—key processes in heart health and disease. Structurally, they are organized into subpopulations (intermyofibrillar, subsarcolemmal, perinuclear), and their morphology adapts dynamically in response to physiological and pathological cues including heart failure and ischemia-reperfusion injury. Due to their central role in cardiac function and dysfunction, they are increasingly viewed as systems-level therapeutic targets for cardiovascular conditions, especially heart failure, though they do not represent a single molecular drug target. Summary: “Cardiac mitochondria” is not a conventional single-molecule drug target but represents a critical organelle system whose dysfunction is central to cardiovascular disease, and as such, has become a focus for emerging therapeutics acting on mitochondrial structure, metabolism, and ROS handling. However, in most pharmacological and structured annotation schemes, it is not considered a "target" in the standard sense.

Other names

cardiac mitochondriamyocardial mitochondriacardiac mitochondrial network

Scavenging mitochondrial ROS (e.g., MitoQ) Stabilizing cardiolipin (mitochondrial membrane lipid) to improve respiratory chain function (e.g., Elamipretide) Inhibiting mitochondrial permeability transition pore opening (e.g., Cyclosporine A, NIM811) Modulating substrate utilization and energy metabolism (e.g., SGLT2 inhibitors' heart benefit partly via mitochondria)